BR112022000865A2 - Vacina de peste suína africana - Google Patents
Vacina de peste suína africanaInfo
- Publication number
- BR112022000865A2 BR112022000865A2 BR112022000865A BR112022000865A BR112022000865A2 BR 112022000865 A2 BR112022000865 A2 BR 112022000865A2 BR 112022000865 A BR112022000865 A BR 112022000865A BR 112022000865 A BR112022000865 A BR 112022000865A BR 112022000865 A2 BR112022000865 A2 BR 112022000865A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- swine fever
- african swine
- polypeptides
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 208000007407 African swine fever Diseases 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 241000701386 African swine fever virus Species 0.000 abstract 1
- 229940031626 subunit vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910794.5A GB201910794D0 (en) | 2019-07-29 | 2019-07-29 | Vaccine |
| PCT/GB2020/051808 WO2021019232A1 (en) | 2019-07-29 | 2020-07-28 | African swine fever vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022000865A2 true BR112022000865A2 (pt) | 2022-03-08 |
Family
ID=67990353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022000865A BR112022000865A2 (pt) | 2019-07-29 | 2020-07-28 | Vacina de peste suína africana |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220273788A1 (https=) |
| EP (1) | EP4003412A1 (https=) |
| JP (1) | JP2022542174A (https=) |
| KR (1) | KR20220041144A (https=) |
| CN (1) | CN114375199A (https=) |
| AU (1) | AU2020322191A1 (https=) |
| BR (1) | BR112022000865A2 (https=) |
| CA (1) | CA3148586A1 (https=) |
| CL (1) | CL2022000161A1 (https=) |
| CO (1) | CO2022001782A2 (https=) |
| GB (1) | GB201910794D0 (https=) |
| MX (1) | MX2022001028A (https=) |
| PH (1) | PH12022550063A1 (https=) |
| TW (1) | TW202118771A (https=) |
| WO (1) | WO2021019232A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373119A (zh) * | 2021-06-02 | 2021-09-10 | 江西农业大学 | 一种表达非洲猪瘟病毒三基因缺失重组伪狂犬病毒毒株、构建方法及其应用 |
| CN116444653B (zh) * | 2023-03-09 | 2024-03-15 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用 |
| CN116284261B (zh) * | 2023-04-04 | 2024-04-19 | 中国人民解放军军事科学院军事医学研究院 | 一种非洲猪瘟病毒结构蛋白组合物及其制备的疫苗 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23544A1 (es) * | 2006-02-28 | 2010-06-17 | Ct Ingenieria Genetica Biotech | Antígenos vacunales quiméricos contra el virus de la peste porcina clásica |
| ES2337113B1 (es) * | 2007-04-17 | 2011-01-24 | Centre De Recerca En Sanitat Animal (Cresa) | Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante. |
| WO2009008888A1 (en) * | 2007-07-10 | 2009-01-15 | Matthias Rath | African swine virus polypeptides as vaccines and its therapeutic use thereof |
| EP2202298A1 (en) * | 2008-12-23 | 2010-06-30 | Stichting Dienst Landbouwkundig Onderzoek | Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV |
| WO2014005643A1 (en) * | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| WO2017096341A2 (en) * | 2015-12-04 | 2017-06-08 | The Texas A&M University System | Adenovirus-vectored multivalent vaccine |
| RU2654586C2 (ru) * | 2016-04-20 | 2018-05-21 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии", (ФГБНУ ФИЦВиМ) | Рекомбинационная кассета, содержащая гены EP153R и EP364R штамма Congo (КК-262) вируса африканской чумы свиней и рекомбинантный штамм ΔСongoCD2v вируса африканской чумы свиней |
| WO2021176235A1 (en) * | 2020-03-06 | 2021-09-10 | The Pirbright Institute | Vaccine against african swine fever virus infection |
-
2019
- 2019-07-29 GB GBGB1910794.5A patent/GB201910794D0/en not_active Ceased
-
2020
- 2020-07-28 TW TW109125471A patent/TW202118771A/zh unknown
- 2020-07-28 CN CN202080062696.4A patent/CN114375199A/zh active Pending
- 2020-07-28 WO PCT/GB2020/051808 patent/WO2021019232A1/en not_active Ceased
- 2020-07-28 MX MX2022001028A patent/MX2022001028A/es unknown
- 2020-07-28 US US17/628,286 patent/US20220273788A1/en active Pending
- 2020-07-28 AU AU2020322191A patent/AU2020322191A1/en active Pending
- 2020-07-28 BR BR112022000865A patent/BR112022000865A2/pt unknown
- 2020-07-28 KR KR1020227006051A patent/KR20220041144A/ko active Pending
- 2020-07-28 EP EP20751252.6A patent/EP4003412A1/en active Pending
- 2020-07-28 CA CA3148586A patent/CA3148586A1/en active Pending
- 2020-07-28 PH PH1/2022/550063A patent/PH12022550063A1/en unknown
- 2020-07-28 JP JP2022505456A patent/JP2022542174A/ja active Pending
-
2022
- 2022-01-24 CL CL2022000161A patent/CL2022000161A1/es unknown
- 2022-02-21 CO CONC2022/0001782A patent/CO2022001782A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114375199A (zh) | 2022-04-19 |
| JP2022542174A (ja) | 2022-09-29 |
| MX2022001028A (es) | 2022-02-23 |
| GB201910794D0 (en) | 2019-09-11 |
| AU2020322191A1 (en) | 2022-03-03 |
| EP4003412A1 (en) | 2022-06-01 |
| PH12022550063A1 (en) | 2023-04-12 |
| TW202118771A (zh) | 2021-05-16 |
| KR20220041144A (ko) | 2022-03-31 |
| CL2022000161A1 (es) | 2022-10-21 |
| CO2022001782A2 (es) | 2022-06-21 |
| US20220273788A1 (en) | 2022-09-01 |
| WO2021019232A1 (en) | 2021-02-04 |
| CA3148586A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011687A (es) | Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas. | |
| BR112022000865A2 (pt) | Vacina de peste suína africana | |
| BR112022005143A2 (pt) | Desenvolvimento de nova vacina contra a peste suína africana viva atenuada baseada na exclusão do gene i177l | |
| AR122899A1 (es) | Combinación de vacunas | |
| AR121361A1 (es) | Vacuna | |
| ZA202004980B (en) | A modified raav capsid protein for gene therapy | |
| BR112017022298A2 (pt) | geranilgeranil pirofosfato sintase | |
| CO2022014256A2 (es) | Vacuna contra la infección por el virus de la peste porcina africana | |
| BR112021026439A2 (pt) | Vacina para febre suína africana | |
| MX2020001402A (es) | Metodos de terapia genica del factor viii (fviii). | |
| BR112022000710A2 (pt) | Vacina viral terapêutica | |
| MX2019003116A (es) | Nueva vacuna contra la gripe porcina. | |
| BR112018000656A2 (pt) | peptídeos para uso na promoção do transporte de glicose | |
| EP2552490A4 (en) | INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF | |
| PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
| MX377803B (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| BR112023027401A2 (pt) | Antígenos do vírus influenza | |
| BR112022024063A2 (pt) | Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina | |
| BR112022011885A2 (pt) | Molécula de ácido nucleico, composição imunogênica, peptídeo, e, métodos para induzir uma resposta imune e para tratar ou prevenir uma patologia | |
| UY39582A (es) | Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov- 2 y/o la prevención de la infección por coronavirus relacionada con el sarscov- 2 | |
| UY39396A (es) | Vacuna basada en aav5 para la inducción de inmunidad específica contra el sarscov-2 y/o la prevención de la infección por coronavirus relacionada con el sarscov-2 | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| BR112018069332A2 (pt) | composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer | |
| BR112013029596B8 (pt) | Composição imunogênica | |
| PE20201405A1 (es) | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante |